You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
A recent study highlights the ability of the company's prognostic tool to detect levels of circulating tumor cells in angiosarcoma patients.
At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.
Following recent publications and anticipating the readout from its NILE study next year, the company plans to make the case that its liquid biopsy approach performs as well as tissue tests.
The company reported revenues of $21.7 million compared to $11.1 million in the year-ago quarter, overshooting analysts' expectations of $17.5 million.
Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.
Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.
Analysts cited Guardant's strong liquid biopsy testing portfolio, specifically its Guardant360 assay, as reasons for their optimistic views.
The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.